Skip to main content

Table 2 Characteristics of Included Studies

From: Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review

Primary reference, Study, Country (secondary references) Objectives Design Sample size Patient population Follow-up
Treatment-related observational studies
Driessen 2008[68], Radboud University Registry, The Netherlands (Driessen 2009[69]) Efficacy and tolerability of etenercept and efalizumab Registry 118 Psoriasis 24 weeks
Fortune 2003[6], PUVA Study, UK and Ireland Role of psychological distress on PUVA treatment outcomes Cohort 112 Plaque psoriasis (chronic) 2 years
Lecha 2005[70], Spanish tacalcitol ointment study Efficacy and tolerability of tacalcitol Cohort 556 Psoriasis (moderate) 2 months
Naldi 2008[71], Psocare, Italy Effect of BMI on clinical response to systemic treatment Cohort 2368 Plaque psoriasis 3 years
Paul 2003[72] Cyclosporine study, Europe and Canada Incidence of malignancies in cyclosporine treated patients Cohort 1252 psoriasis - severe 5 years
Wahl 2005[73], Climate therapy study, Norway Effectiveness of climate therapy Cohort 286 Psoriasis 8 months
Heiberg 2008[74], Norwegian register of disease modifying anti-rheumatic drugs, (Heiberg 2007[75]) Comparative effectiveness of TNF inhibitors vs. methotrexate monotherapy Registry 526 Psoriatic arthritis 1 year
Kristensen 2008[76], South Swedish Arthritis Treatment Group register, (Gulfe 2009[77], Geborek 2002[78], Kristensen 2006[79]) Efficacy, utility and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab) Registry 261 Psoriatic arthritis 7 years
Sparado 1997[80], Cyclosporin Study, Italy Probability of continuing to take cyclosporine vs. other DMARDS Cohort 172 Psoriatic arthritis 10 years
Saad 2009[81], British Society for Rheumatology Biologics Register, (Harrison 2009[82], Silman 2003[83]) Effectiveness and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab) Registry 566 RA, psoriasis, psoriatic arthritis 1 year
Non-treatment related observational studies
Carrascosa 2006[84], EPIDERMA cost of illness, Spain Direct and indirect cost; relationship between cost and severity Cohort 797 Psoriasis 1 year
Colombo 2008[11], Cost of illness, Italy Direct and indirect cost; HRQOL; relationship between cost, HRQOL and severity Cohort 150 Moderate to severe plaque psoriasis 3 months
Schmid-ott 2005[85], Bad Bentheim Rehabilitation Hospital, Germany Relationship between the degree of stigmatisation and gender, skin symptoms, PASI and SPASI Cohort 166 Psoriasis 1 year
Ali 2007[86], Husted 2007[2], Gladman 2009[16], Rohekar 2008[87], Toronto PsA clinic, Canada, (Chandran 2007[88], Gladman 1995[89], Gladman 1998[90], Gladman 1999 [91], Gladman 2001[92], Husted 2005[93], Wong 1997[94]) (1) Mortality associated with PsA; (2) relationship between physical functioning, disease activity and joint damage; (3) CVD associated with PsA; (4) malignancies associated with PsA Cohort 382 to 680 Psoriatic arthritis 26 years
Kane 2003[95], St. Vincent's University study, Ireland, (Kane 2003a[96]) Clinical presentation, outcome and prognosis of early PsA Cohort 129 Early psoriatic arthritis 2 years
Lindqvist 2008[97], SwePsA registry, Sweden, (Svensson 2002[98]) Factors associated with disease progression; outcome of treated and non-treated groups, comparison of outcomes with RA patients Registry 135 Early psoriatic arthritis 2 years
  1. PUVA, Psoralen Ultra-Violet A. TNF, Tumor Necrosis Factor. DMARD, disease-modifying anti-rheumatic drug. RA, rheumatoid arthritis. HRQOL, health-related quality of life.